本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、情况概述 证券代码：300030 证券简称：阳普医疗 公告编号：2026-002 阳普医疗科技股份有限公司 关于全资子公司收到医疗器械变更注册（备案）文件的公告 本次医疗器械注册证书变更使产品能更好地满足市场需求，有利于增强公司 的市场竞争力，对公司未来发展有积极影响。 上述产品实际销售情况可能受到市场环境等因素影响，对公司未来经营业绩 的影响存在不确定性。敬请广大投资者给予关注并注意投资风险。 2026 年 2 月 6 日 三、备查文件 《中华人民共和国医疗器械变更注册（备案）文件》。 特此公告。 阳普医疗科技股份有限公司董事会 近日，阳普医疗科技股份有限公司（以下简称"公司"）全资子公司广州阳 普医疗器械有限公司（以下简称"阳普器械"）收到由广东省药品监督管理局核 发的《中华人民共和国医疗器械变更注册（备案）文件》，具体情况如下： | 产品名称 | 注册证编号 | 注册 | 注册证 | 主要变更内容 | | --- | --- | --- | --- | --- | | | | 分类 | 有效期至 | | ...

Core Viewpoint - Yangpu Medical (300030.SZ) expects to achieve a net profit attributable to shareholders of 12 million to 17.5 million yuan in 2025, marking a turnaround from losses, with a net profit excluding non-recurring gains and losses projected at 16.5 million to 24 million yuan, also indicating a return to profitability [1] Group 1: Financial Performance - The company anticipates a year-on-year decline in operating revenue of 15% to 20% during the reporting period [1] - Revenue from vacuum blood collection system products is primarily affected by a decrease in sales, leading to a downward trend in income [1] - Revenue from reagents, software products, and services is also expected to decline year-on-year [1]

Group 1 - The core viewpoint of the article is that Yangpu Medical has announced an expected net profit for 2025, which is projected to be between 12 million and 17.5 million yuan for the shareholders of the listed company [2] Group 2 - The announcement was made on January 28, indicating the company's forward-looking financial expectations [2] - The projected net profit range reflects a specific financial outlook for the company, which may influence investor sentiment and market performance [2]

Core Viewpoint - The company expects a significant improvement in net profit for 2025, projecting a range of 12 million to 17.5 million yuan, compared to a loss of 118 million yuan in the same period last year [1] Revenue Performance - The company's operating revenue is anticipated to decline by 15% to 20% year-on-year [1] - The vacuum blood collection system products are primarily affected by a decrease in sales, leading to a downward trend in revenue [1] - Revenue from reagents, software products, and services is also expected to see a year-on-year decline [1] Cost Management - The company has implemented systematic cost optimization measures and refined management practices, effectively reducing manufacturing costs [1] - Despite a downward trend in product prices, the company has successfully achieved a slight increase in gross margin year-on-year [1] - The total expenses and expense ratio have decreased year-on-year due to reasonable control of expenditures and continuous optimization of the expense structure [1]

Financial Performance Expectations - The company expects a net profit of between 12 million and 17.5 million yuan for 2025, a significant turnaround from a loss of 117.9 million yuan in the same period last year[4] - The net profit after deducting non-recurring gains and losses is projected to be between 16.5 million and 24 million yuan, compared to a loss of 69.98 million yuan in the previous year[4] - Non-recurring gains and losses are expected to negatively impact net profit attributable to shareholders by 5 million to 7.5 million yuan, a significant improvement from the previous year's impact of 47.93 million yuan[7] Revenue and Sales Outlook - The company's operating revenue is expected to decline by 15% to 20% year-on-year, primarily due to decreased sales of vacuum blood collection system products[6] Cost Management and Profitability - Despite the decline in product prices, the company has successfully improved its gross margin slightly year-on-year through systematic cost optimization and refined management[6] - The company anticipates a decrease in impairment losses for goodwill, inventory, fixed assets, and credit losses compared to the previous year[7] Investment and Income - Investment income is expected to increase year-on-year, mainly due to the company's stake in Shenzhen Yanghe Biomedical Industry Investment Co., which holds shares in Nanjing Weisi Medical Technology Co., Ltd.[7] Financial Reporting - The financial data presented is preliminary and has not been audited by the accounting firm, with the final figures to be disclosed in the official 2025 annual report[8]

| 产品名称 | 注册证编号 | 注册 | 注册证 | 主要变更内容 | | --- | --- | --- | --- | --- | | | | 分类 | 有效期至 | | | 一次性使用人体末梢 | 粤械注准 | Ⅱ类 | 2028.12.28 | 1.结构及组成变更； | | 血样采集容器 | 20182220296 | | | 2.产品技术要求变更。 | 二、对公司的影响及风险提示 阳普医疗科技股份有限公司 关于全资子公司收到医疗器械变更注册（备案）文件的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、情况概述 近日，阳普医疗科技股份有限公司（以下简称"公司"）全资子公司广州阳 普医疗器械有限公司（以下简称"阳普器械"）收到由广东省药品监督管理局核 发的《中华人民共和国医疗器械变更注册（备案）文件》，具体情况如下： 证券代码：300030 证券简称：阳普医疗 公告编号：2025-055 本次医疗器械注册证书变更使产品能更好地满足市场需求，有利于增强公司 的市场竞争力，对公司未来发展有积极影响。 上述产品实际销售情况可能受到市场环境等因素影响 ...

Group 1 - The article reports on the compliance inspections of seven pharmaceutical manufacturing companies in accordance with Chinese regulations, including the Drug Administration Law and related guidelines [2] - The inspections were conducted by the Shaanxi Provincial Drug Supervision Administration, focusing on the quality management standards of the companies [2] - The companies inspected include Huadong Medicine (Xi'an) Bohua Pharmaceutical Co., Shaanxi Hanjiang Pharmaceutical Group, and others, with specific production lines and products evaluated [2] Group 2 - The inspection results indicate that all companies inspected were found to be compliant with the relevant quality management standards [2] - Specific products inspected include raw materials like Topiramate and formulations such as Sirolimus gel, with detailed information on production lines and facilities provided [2] - The inspections took place between October 13 and October 31, 2025, across various locations in Shaanxi Province [2]

阳普医疗科技股份有限公司 2025年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会不存在增加、变更、否决议案的情况； 证券代码：300030 证券简称：阳普医疗 公告编号：2025-054 （二）中小股东出席的总体情况 通过现场和网络投票的中小股东（中小股东是指除单独或合计持有上市公司 5%以上股份的股东及除公司的董事、监事、高级管理人员以外的其他股东）125 人，代表股份 1,306,850 股，占公司总股份的 0.4227％。其中：通过现场投票 的中小股东 0 人，代表股份 0 股，占公司总股份的 0.0000％；通过网络投票的 中小股东 125 人，代表股份 1,306,850 股，占公司总股份的 0.4227％。 二、议案审议情况 2.本次股东会不存在变更前次股东会决议的情况； 3.本次股东会以现场与网络投票相结合的方式召开。 一、会议召开和出席情况 阳普医疗科技股份有限公司（以下简称"公司"）2025 年第一次临时股东 会于 2025 年 11 月 27 日下午 15:30 在公司 2 号会议室召 ...

北京市中伦（广州）律师事务所 关于阳普医疗科技股份有限公司 法律意见书 2025 年第一次临时股东会的法律意见书 致：阳普医疗科技股份有限公司 北京市中伦（广州）律师事务所（以下简称"本所"）受阳普医疗科技股份 有限公司（以下简称"公司"）委托，指派程俊鸽律师、熊鑫律师（以下简称"本 所律师"）出席公司 2025 年第一次临时股东会（以下简称"本次股东会"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市 公司股东会规则》等法律、法规、规范性文件及《阳普医疗科技股份有限公司章 程》（以下简称"《公司章程》"）、《阳普医疗科技股份有限公司股东大会议 事规则》的规定，对公司本次股东会进行见证并出具法律意见。 为出具本法律意见书，本所律师审查了公司本次股东会的有关文件和材料。 本所律师得到公司如下保证，即其已提供了本所律师认为作为出具本法律意见书 所必需的材料，所提供的原始材料、副本、复印件等材料、口头证言均符合真实、 准确、完整的要求，有关副本、复印件等材料与原始材料一致。 在本法律意见书中，本所律师仅对本次股东会的召集、召开程序、出席本次 股东会人员和召集人的资格、会议表决程序及表决结 ...

Core Insights - The precision medicine sector experienced a 1.92% increase on November 24, with Guomai Technology leading the gains [1] - The Shanghai Composite Index closed at 3836.77, up 0.05%, while the Shenzhen Component Index closed at 12585.08, up 0.37% [1] Stock Performance - Guomai Technology (002093) closed at 12.19, up 10.02% with a trading volume of 446,600 shares and a transaction value of 536 million [1] - Zhongyuan Xiehe (600645) also rose by 10.02% to 28.23, with a trading volume of 169,100 shares and a transaction value of 468 million [1] - Other notable performers include: - Toukeng Life (300642) at 19.51, up 3.34% [1] - Beirui Gene (000710) at 11.97, up 3.28% [1] - Yangjin Medical (300030) at 7.90, up 3.27% [1] Capital Flow - The precision medicine sector saw a net inflow of 526 million from institutional investors, while retail investors experienced a net outflow of 143 million [2] - The main capital inflow and outflow for key stocks include: - WuXi AppTec (603259) with a net inflow of 251 million [3] - Guomai Technology (002093) with a net inflow of 241 million [3] - Zhongyuan Xiehe (600645) with a net inflow of 102 million [3]